Clinical trials: Osteoporosis Postmenopausal
Osteoporosis, Postmenopausal
Pearlium®/Effecti-Cal®, a Novel Formulation of Calcium, Vitamin D and Minerals for Prevention of Postmenopausal Bone Loss
Postmenopausal osteoporosis is one of the important medical disorders affecting women after menopause. It is characterized by bone loss and reduced bone strength. In turn, this leads to increased risk of fracture.
- Trial name
- NCT04609189
- Testing
- Pearlium/EffectiCal, Calcium carbonate/vitamin D3
- Volunteers
- 97 people
- Sponsor
- University of Alberta
Postmenopausal Osteoporosis
BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis
This 2 arm study will assess the impact of Bone Marker Feedback (BMF), using blood sampling and communication of the results at 2 months, on adherence to monthly Bonviva (150mg po) in women with post-menopausal osteoporosis.
- Trial name
- NCT00545909
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 57 sites in Austria, Belgium and 3 more
- Volunteers
- 585 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis, Post-menopausal
Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes
The goal of this clinical trial is to learn if romosozumab (Evenity) can improve bone and muscle health in postmenopausal women with osteoporosis who are undergoing lumbar spine surgery.
- Trial name
- NCT06973109
- Testing
- Romosozumab, Alendronate (Fosamax)
- Where
- United States
- Sponsor
- University of Pittsburgh
Osteopenia, Osteoporosis
Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis
Osteoporosis, a condition in which bones are fragile and break easily, is a major health problem for postmenopausal women. Research studies have shown that both estrogen/progestin replacement therapy (hormone replacement therapy…
- Trial name
- NCT00000430
- Testing
- Alendronate, Estrogen/progestin therapy
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Postmenopausal Osteoporosis
Open-label Study to Evaluate the Effect of MBP-80 on Bone Remodelling
This study will determine if daily oral intake of 200g of a marketed yogurt with fortified calcium content and a milk basic protein (MBP)80 mg benefits on bone cells activity in postmenopausal women.
- Trial name
- YogA (NCT01501344)
- Testing
- 200 g yogurt with fortified calcium content and MBP 80 mg
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Groupe De Recherche En Rhumatologie Et Maladies Osseuses Inc.
Post Menopausal Osteoporosis
Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France
The purpose of the study is to describe the characteristics and management of post menopausal women with osteoporosis treated with Prolia in France, and examine the use of Prolia in routine clinical practice in France
- Trial name
- PILOTE (NCT02347865)
- Testing
- AMG 162 - Prolia
- Where
- France
- Volunteers
- 777 people
- Sponsor
- Amgen
Osteoporosis
The Effect of Vitamin K2 on Bone Turnover
To investigate the effect of menatetrenone on bone turnover in postmenopausal patients with osteoporosis. One month of menatetrenone therapy enhanced the secretion and gamma-carboxylation of osteocalcin.
- Trial name
- NCT00548509
- Testing
- Menatetrenone (Vitamin K2)
- Where
- 4 sites in Japan
- Volunteers
- 131 people
- Sponsor
- Eisai Limited
Osteoporosis, Postmenopausal
Satisfaction and Compliance of Risedronate in PMO
Compare subject satisfaction of once a week dosing of 35 mg Risedronate to once daily dosing of 5 mg Risedronate in postmenopausal osteoporotic women.
- Trial name
- NCT00549965
- Testing
- Risedronate Sodium
- Where
- South Korea
- Volunteers
- 202 people
- Sponsor
- Sanofi
Postmenopausal Period, Osteoporosis, Postmenopausal
Angeliq Regulatory Post Marketing Surveillance
Angeliq regulatory Post-Marketing Surveillance (PMS) is to get data about safety and efficacy in real practice for the indication approved by Korea Food and Drug Administration (KFDA).
- Trial name
- Angeliq rPMS (NCT01064453)
- Testing
- E2/DRSP (Angeliq, BAY86-4891)
- Where
- South Korea
- Volunteers
- 4,078 people
- Sponsor
- Bayer
Osteoporosis
Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
This study will compare the effects of Zoledronic acid and Raloxifene in reducing bone turnover markers in postmenopausal women with low bone mineral density over 6 months.
- Trial name
- NCT00431444
- Testing
- Raloxifene, Zoledronic acid
- Where
- 17 sites in United States
- Volunteers
- 110 people
- Sponsor
- Novartis
Bone Diseases, Metabolic
Dried Plums for Bone Health in Older Postmenopausal Women
The objective of the investigators current study was to examine whether 50 g dried plum would be as effective as 100 g dried plum in reversing bone loss in osteopenic older postmenopausal women.
- Trial name
- NCT02325895
- Testing
- Dried Plum
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- San Diego State University
Osteoporosis, Osteopenia
High Dosage Vitamin D and Osteoporosis
Vitamin D and calcium are essential in the treatment and prevention of osteoporosis. What dosage of vitamin D which is the ideal one, is not yet clear. We want to test the hypothesis that high dosage of vitamin D (i.e.
- Trial name
- NCT00491920
- Testing
- cholecalciferol (Vitamin D3)
- Where
- Norway
- Volunteers
- 297 people, healthy volunteers welcome
- Sponsor
- University Hospital of North Norway
Osteoporosis, Osteoporosis, Postmenopausal
Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
This two-year observational, open-label clinical trial will evaluate the efficacy of a once-yearly infusion of zoledronic acid after denosumab discontinuation to maintain tissue mineral density and bone microarchitecture using…
- Conditions
- Osteoporosis, Osteoporosis, Postmenopausal, Osteopenia, Bone Loss
- Trial name
- NCT05405894
- Testing
- Zoledronic acid
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of Calgary
Postmenopausal Osteoporosis
G56W1 in Women With Postmenopausal Osteoporosis
This study will assess the pharmacokinetics and safety and explore therapeutic effects with once-weekly recombinant human parathyroid hormone for injection ( 1-34 ) ( G56W1 ) in women with post-menopausal osteoporosis .The…
- Trial name
- NCT03720886
- Testing
- rhPTH（1-34） 28.2μg, rhPTH（1-34） 56.5μg, teriparatide acetate(Teribone™)
- Where
- 9 sites in China
- Volunteers
- 148 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Rheumatoid Arthritis
Clinical Trial on the Efficacy of Raloxifene on Disease Activity in Rheumatoid Arthritis
The investigators select 40 postmenopausal women suffering from RA with 2.5<DAS28<5.5 referring to rheumatology clinics of Mashhad university of medical sciences and randomly divide them into intervention group and placebo group.
- Trial name
- NCT02982083
- Testing
- Raloxifene hydrochloride
- Volunteers
- 34 people
- Sponsor
- Sara Saeidi Shahri
Postmenopausal Osteoporoses
Clinical Study on Treatment of Postmenopausal Osteoporosis (Kidney Deficiency and Blood Stasis Syndrome) With Xulin Jiangu Granules
Osteoporosis is a common senile disease with a high incidence. The Chinese medicine differentiation treatment has small side effects and can be taken for a long time, which has certain advantages.
- Trial name
- CSOPOPWXJG (NCT03563235)
- Testing
- Xulin Jiangu granules, Calcitriol capsules
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fujian Academy of Traditional Chinese Medicine
Osteoporosis
A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-751689 Administered to Healthy Women
This study will examine the effects of formulation on the relative bioavailability of SB-751689 (400 mg) administered to healthy postmenopausal women.
- Trial name
- NCT00540878
- Testing
- SB-751689 oral tablets (400 mg)
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Menopause, Osteoporosis
Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
The purpose of this research study is to evaluate the safety and effectiveness of this investigational drug for the treatment of menopausal symptoms while protecting the endometrium (uterine lining) and preventing postmenopausal…
- Trial name
- NCT00808132
- Testing
- bazedoxifene 20 mg/ conjugated estrogens 0.45 mg, bazedoxifene 20 mg/ conjugated estrogens 0.625 mg, bazedoxifene 20 mg
- Where
- 178 sites in United States, Argentina and 10 more
- Volunteers
- 1,886 people
- Sponsor
- Pfizer
Post Menopausal Osteoporosis
Evaluation of Adherence With Bisphosphonates and Calcium and Vitamin D Supplements in Women With Postmenopausal Osteoporosis
This study aims to evaluate the adherence of patients to combined treatment with bisphosphonates and calcium and vitamin D supplements, which is one of the usual treatments for postmenopausal osteoporosis.
- Trial name
- OSTEOAD (NCT07105163)
- Where
- 20 sites in Spain
- Volunteers
- 230 people
- Sponsor
- Procare Health Iberia S.L.
Fractures, Osteoporosis
OSTPRE-Fracture Prevention Study
The purpose of this study is to determine the effect of calcium 1000 mg/d and vitamin-D3 800 IU/d divided in two daily doses on the incidence of falls and fractures, bone mineral density and bone metabolism in postmenopausal…
- Trial name
- OSTPRE-FPS (NCT00592917)
- Testing
- calcium carbonate and cholecalciferol
- Where
- Finland
- Volunteers
- 3,432 people
- Sponsor
- Kuopio University Hospital